吡格列酮联合二甲双胍治疗激素抵抗性PCOS不孕对患者性激素、炎症因子水平的影响

doi:10.3969/j.issn.1671-7171.2022.05.011

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1157 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨吡格列酮联合二甲双胍治疗激素抵抗性多囊卵巢综合征(PCOS)不孕对患者性激素、炎症因子水平的影响。【方法】选取120例激素抵抗性PCOS不孕患者,按随机数字表法分成观察组与对照组,每组60例。对照组采用二甲双胍治疗,观察组在对照组基础上加用吡格列酮治疗,比较两组临床疗效、治疗期间不良反应及治疗前后胰岛素抵抗(IR)指标[空腹血糖(FPG)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)]、性激素[促卵泡生成素(FSH)、促黄体生成素(LH)、睾酮(T)、雌二醇(E₂)]及炎症因子[白细胞介素-6(IL-6)、白细胞介素-17(IL-17)、肿瘤坏死因子(TNF-α)、超敏C反应蛋白(hs-CRP)]水平。【结果】观察组患者总有效率为95.00%,明显高于对照组的80.00%,其差异有统计学意义(P<0.05)。与本组治疗前比较,两组治疗后FPG、FINS、HOMA-IR、FSH、LH、T、E₂、IL-6、IL-17、TNF-α、hs-CRP均明显降低(P<0.05);治疗后,观察组FPG、FINS、HOMA-IR、FSH、LH、T、E₂、IL-6、IL-17、TNF-α、hs-CRP均显著低于对照组,其差异有统计学意义(P<0.05)。治疗期间,两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】吡格列酮联合二甲双胍治疗激素抵抗性PCOS不孕患者,可有效提高临床疗效,可改善血糖代谢和性激素水平,抑制炎性反应,且安全性较高,值得临床推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	胡晓英
	邢忠莹
	曹婷婷
	倪晓红

关键词 ：多囊卵巢综合征, 不育,女(雌)性, 二甲双胍/药理学, 噻唑类/药理学, 性腺甾类激素

Abstract：【Objective】 To observe the effects of pioglitazone and metformin on the levels of sex hormones and inflammatory factors in the treatment of infertility with hormone resistant polycystic ovary syndrome (PCOS). 【Methods】 A total of 120 infertile patients with hormone resistant PCOS were randomly divided into the observation group (n=60) and the control group (n=60).The control group was treated with metformin alone and the observation group was treated with pioglitazone in addition to metformin. The clinical efficacy, adverse reactions, insulin resistance(IR) index before and after treatment [fasting plasma glucose(FPG),fasting insulin (FINS),insulin resistance index(HOMA-IR)],sex hormone [follicle-stimulating hormone (FSH),luteinizing hormone(LH),testosterone(T),estradiol(E₂)] level and inflammation related index [interleukin 6(IL-6),interleukin-17(IL-17),tumor necrosis factor-α(TNF-α),high sensitivity C-reactive protein(hs-CRP)] were compared between the two groups.【Results】 The total effective rate in the observation group was 95.00%,which was significantly higher than 80.00% in the control group (P<0.05).After treatment, FPG,FINS, HOMA-IR, FSH,LH,T,E₂,IL-6,IL-17,TNF-αand hs-CRP were significantly decreased in the two groups compared with before treatment (P<0.05). Levels of FPG,FINS, HOMA-IR,FSH,LH,T,E₂,IL-6,IL-7 TNF-αand hs-CRP in the observation group after treatment were significantly lower than those in the control group; And the differences were statistically significant (P<0.05). During the treatment period, there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】 On the basis of metformin in the treatment of hormone resistant PCOS infertility, pioglitazone can effectively improve the clinical efficacy, which can have obvious blood glucose metabolism improvement, adjust the level of sex hormones, inhibit the inflammatory reaction. Safety of the drug is high, so it is worthy of clinical promotion.

Key words： Polycystic Ovary Syndrome Infertility, Female Metformin/PD Thiazoles/PD Gonadal Steroid Hormones

收稿日期: 2022-01-05

中图分类号:

R711.75

通讯作者: *E-mail:1034180132@qq.com

引用本文:

胡晓英, 邢忠莹, 曹婷婷, 倪晓红. 吡格列酮联合二甲双胍治疗激素抵抗性PCOS不孕对患者性激素、炎症因子水平的影响[J]. 医学临床研究, 2022, 39(5): 678-681.
HU Xiao-ying, XING Zhong-ying, CAO Ting-ting, et al. Effects of Pioglitazone and Metformin on the Levels of Sex Hormones and Inflammatory Factors in the Treatment of Hormone Resistant PCOS Infertility. JOURNAL OF CLINICAL RESEARCH, 2022, 39(5): 678-681.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.05.011 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I5/678

[1] RUAN X, LI M, MUECK A O. Why Polycystic Ovary Syndrome (PCOS) needs long-term management?[J].Current Pharmaceutical Design,2019, 25(39):4685-4692.
[2] REN N, KIM E, LI B, et al. Flavonoids alleviating insulin resistance through inhibition of inflammatory signaling[J].J Agric Food Chem,2019, 67(19):5361-5373.
[3] NA M A. Effect of ethinylestradiol cyproterone combined with pioglitazone or metformin in treatment of polycystic ovary syndrome[J].Drug Evaluation,2018, 15(10):26-29.
[4] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome(PCOS) [J].Hum Reprod,2004, 19(1):41-47.
[5] 中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志, 2018, 53(1):2-6.
[6] 李墨, 华苓. 多囊卵巢综合征胰岛素抵抗的新进展[J].国际妇产科学杂志, 2011,39(4):358-363.
[7] HE F F, LI Y M. Role of gut microbiota in the development of insulin resistance and the mechanism underlying polycystic ovary syndrome: A review[J].J Ovarian Res,2020, 13(1):73.
[8] LANG V B, BARETI M. Letter to the editor regarding: continuous glucose monitoring in Type 2 Diabetes mellitus patients in primary care[J].Adv Ther,2020, 37(3):1276-1278.
[9] TAUQIR S, ISRAR M, RAUF B, et al. Acetyl-L-carnitine ameliorates metabolic and endocrine alterations in women with pcos:a double-blind randomized clinical trial[J].Adv Ther,2021, 38(9):3842-3856.
[10] NAGAO S, BABA T, FUJIBE Y, et al. Pioglitazone suppresses excessive follicular development in murine preantral follicles[J].J Ovarian Res,2019, 12(1):82.
[11] PATEL R, SHAH G. Insulin sensitizers modulate GnRH receptor expression in PCOS rats[J].Arch Med Res,2018, 49(3):154-163.
[12] 肖玲, 古智兵, 刘颦, 等. 特应性体质肺炎支原体感染患儿临床特点及血清IL-17的水平研究[J].中华医院感染学杂志, 2018,28(2):4.